## HCA: HCA Healthcare, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.27 indicates fundamental undervaluation. Quality metrics strong (ROE 136%, ROA 12%). Consistent execution (4/4 quarters beat estimates). Caution: momentum weakening (-5.4% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($462.76)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 8, Bearish: 0)

**1. 2 Soaring Healthcare Stocks to Buy and Hold for a Decade**
- Source: Finviz | 20251204T120942 | Bullish | Relevance: 100%
- This article highlights HCA Healthcare (NYSE: HCA) and CVS Health (NYSE: CVS) as two healthcare stocks with significant upside potential over the next decade. Both companies have seen impressive stock performance in the past year, and the author argues they are well-positioned for future growth due to strategic initiatives, an aging population, and expanding market reach.

**2. HCA’s Cash Machine Looks Cheap After A Healthy Run**
- Source: Finimize | 20251203T145120 | Somewhat-Bullish | Relevance: 100%
- HCA Healthcare, the largest for-profit hospital operator in the U.S., has shown strong recent performance with a 56.6% total return over 12 months and raised full-year guidance for 2025. Despite policy risks and labor cost inflation, its robust cash generation, strong margins, and perceived valuation discount make it an appealing opportunity for long-term investors, though the stock carries risks associated with leverage and regulatory uncertainty.

**3. HCA Healthcare Stock Near Record Highs: December 2025 Earnings, Forecasts and Policy Risks Explained**
- Source: ts2.tech | 20251203T003617 | Bullish | Relevance: 100%
- HCA Healthcare (NYSE: HCA) is approaching record highs in December 2025, driven by strong earnings growth, upgraded guidance, and a strategic focus on outpatient expansion. The article details HCA's financial performance, analyst sentiment, and potential policy risks like the expiration of ACA premium tax credits. While momentum is strong, some analysts suggest the stock might be overextended in the short term.

**4. HCA Healthcare announces $4.8 million gift to help launch Pepperdine University's School of Nursing**
- Source: marketscreener.com | 20251205T135927 | Bullish | Relevance: 100%
- HCA Healthcare has donated $4.8 million to Pepperdine University to support the launch of its new School of Nursing. This significant gift will aid in developing the school's programs and facilities, enhancing nursing education. The announcement underscores HCA Healthcare's commitment to advancing healthcare education and addressing the growing demand for skilled nursing professionals.

**5. HCA Healthcare Announces $4.8 Million Gift to Help Launch Pepperdine University’s School of Nursing**
- Source: Yahoo Finance Singapore | 20251205T133227 | Bullish | Relevance: 100%
- HCA Healthcare is donating $4.8 million to Pepperdine University to establish its new School of Nursing, aiming to address the national nursing shortage. This gift will support the development of a 30,000-square-foot facility and provide clinical rotation opportunities for students at HCA Healthcare's Los Robles Regional Medical Center. The School of Nursing, which opened this fall, offers undergraduate and graduate programs and aligns with HCA Healthcare's broader commitment to nursing education and leadership development.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-13 | Wells Fargo | $431 | $412 | +5% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-13 | Wells Fargo | main | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($3.12M) |
| Sells | 4 ($14.79M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 29.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 2 / 7 |

**Top Holders:**
- Vanguard Group Inc: 6.5% (-3.8%)
- Blackrock Inc.: 5.5% (-3.7%)
- Sanders Capital, LLC: 4.7% (-3.9%)
- State Street Corpora: 3.3% (-5.9%)
- JPMORGAN CHASE & CO: 2.6% (+82.2%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-5.4% 5d) with bearish MACD, trend may be turning.
2. Heavy insider selling: $15M sold (4 transactions in 90 days).
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.27 suggests fair value with growth premium. Forward P/E 16.4x stretched relative to 7% growth. Quality metrics strong (ROE 136%, ROA 12%). Balance sheet: $3.1B free cash flow. Insider selling cluster ($14.8M in 90 days), potential headwind. Institutional flow bullish (2 buying vs 7 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $111.6B |
| Beta | 1.37 |
| 52W Range | $289.98 - $520.00 |
| Short Interest | 2.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.27 |
| Forward P/E | 16.4 |
| Current P/E | 17.6 |
| YoY Growth | 7.3% |
| EPS Direction | RISING |

### Technicals

MRS_20 deteriorating from 3.2% to -2.2% (-5.4% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 6.2pp (needs >4.0% for momentum thesis). Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram bearish (-2.56), momentum weakening. RSI neutral at 55. OFD pattern: -SLL (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -2.20% (CS: 35) | Weak |
| RSI_14 | 54.6 | Neutral |
| MACD Histogram | -2.56 | Bearish |
| vs SMA20 | 1.001x | Above |
| vs SMA50 | 1.063x | Above |
| vs SMA200 | 1.255x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $486.70
- **Stop Loss:** $462.76 (4.9% risk)
- **Target:** $534.58 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 20
- **Position Value:** $9,734.00
- **Portfolio %:** 9.73%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with balanced risk appetite. VIX near 15th percentile of 52-week range signals calm conditions, while modest yield curve steepening (54bps 10Y-3M) suggests healthy growth expectations. Breadth at 52% indicates selective participation rather than broad-based momentum.*

### Earnings

**Next:** 2026-01-23 (Est: $7.46)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $5.73 | $6.96 | +21.6% |
| 2025Q2 | $6.32 | $6.84 | +8.2% |
| 2025Q1 | $5.75 | $6.45 | +12.1% |
| 2024Q4 | $6.14 | $6.22 | +1.2% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*